A2A Pharmaceuticals, Inc. is 10% Owner at Biomea Fusion, Inc. (BMEA). They have made 7 open-market trades across 1 company since 2021, most recently 2023-06-01.
CIK 0001859061
1 open-market purchase totalling $805K since 2021, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BMEA | 3,550,000 | $3.1M |
Shares reported on the most recent Form 4, priced at the 2023-06-02 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 17% | 100% |
| Avg Move | +3.5% | +1.0% | -33.2% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BMEA | SELL | 2023-05-31 | 2023-06-02 | $34.11 | $4.3M | +10.7% | -39.0% | -52.0% |
| BMEA | SELL | 2023-05-12 | 2023-05-17 | $33.84 | $1.7M | +2.9% | +6.3% | -42.1% |
| BMEA | SELL | 2023-05-08 | 2023-05-10 | $34.30 | $8.6M | -2.8% | +25.7% | -43.2% |
| BMEA | SELL | 2023-04-20 | 2023-04-26 | $29.12 | $5.8M | +6.9% | +0.7% | -36.5% |
| BMEA | SELL · Routine | 2023-03-31 | 2023-04-06 | $31.25 | $6.3M | +6.9% | +29.6% | -12.7% |
| BMEA | BUY | 2022-08-16 | 2022-08-19 | $13.87 | $426K | +9.7% | +6.0% | -30.6% |
| BMEA | SELL | 2022-07-21 | 2022-07-25 | $11.21 | $777K | +0.5% | +10.7% | -16.2% |
| BMEA | SELL | 2022-06-24 | 2022-06-28 | $11.76 | $815K | +2.5% | +1.4% | -9.0% |
| BMEA | BUY | 2021-09-17 | 2021-09-21 | $10.96 | $380K | +12.0% | +5.2% | -21.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.